Updated information provided, as we progress through technology and business development, clinical trials for our many use-cases, FDA interactions, and ultimately commercial launches.
March 2026 | Latest Update
Delta Chase LLC | Cincinnati Ohio — DeltaChase in partnership with SightLine Ventures won finalist honors in the competition sponsored by the U.S. Army's xTECH Search group, earning a $250,000 award for its brain-saving technology, CPR4Brain™. The new contract starts April 1st 2026.
The competition, launched in May 2025, seeks to uncover breakthrough technologies to save or improve soldiers’ lives in combat, as well as improving various health conditions for our Veterans community, where our Sleep Apnea product should provide relief to those who continue to struggle with CPAP or have completely abandoned (national averages at 75%+) this modality due to all of its discomforts. This award provides immediate funding for completion of both the SAGE Rebreather™ and the exciting cool comfort under the SAGE mask of the FaceShield™.
'#DeltaChase #SAGErebreather #MedTech #TBI #BrainHealth #AngelInvestors #Military
Download the PDF for more Award details
November 2025 WHITE PAPER “Over the oxygen supply of the body, carbon dioxide spreads its protecting wings” —Yale University 1935 | Value of Inhalation of Carbon Dioxide in Climbing Great Altitudes)
The medical community has appreciated the life sustaining benefits of delivering carbon dioxide (CO2) to humans for more than 100 years. Even though LIFE may have found a way to live without oxygen, LIFE simply cannot exist without CO2. Like water, CO2 is vital for all life on Earth; and specifically, CO2 is not a pollutant nor contaminant, and as such, carbon dioxide cannot intoxicate because it exists as a non-poisonous, non-toxic substance. Of all the world’s organic compounds, carbon dioxide (by far) represents the most important one for the sustainability of the biosphere (the whole of life on Earth). Despite its versatility and non-toxic behavior, Mankind has historically had a “love-hate” relationship with CO2 (e.g., advocates implicating it in “Climate Change”). But notably, physiologically, CO2 is the body’s most ubiquitous and chief hormone of the body; every tissue produces it, and it likely acts on every organ. Critical to this discussion, humans are CARBOXIC BREATHERS, that is, rising CO2 levels stimulate breathing — NOT falling O2 levels.
November 2025 (Original) WHITE PAPER with 29 References outlining the use of CO2 to Mitigate SLEEP APNEA as well as other forms of Sleep Disordered Breathing (SDB) | CO2 rebreathing represents a treatment for SDB, emphasizing Sleep Apnea, collectively affecting nearly one billion people worldwide. CPAP and oral devices have poor compliance rates (20-40%) due to numerous complications, especially discomfort, while CO2 has been shown since the 1980s to reduce apneas and improve sleep quality by stabilizing breathing patterns.
November 2025 (Updated from original in 2008) WHITE PAPER focused on the SAGE Rebreather™ patented TECHNOLOGY PLATFORM that safely increases inhaled CO2 levels to address multiple health conditions including traumatic brain injury (TBI), sleep apnea, high-altitude illness, POTS, and potentially SIDS, plus many more with the potential to impact over one billion people worldwide. The platform has demonstrated proof-of-principle in human studies and leverages a naturally-occurring physiologic mechanism to offer an alternative to expensive gas canisters, currently targeting markets currently spending over $500 billion annually.
November 2025 (Updated from original in 2002) WHITE PAPER focused on the scientific evidence and rationale for controlled therapeutic use of CO2 to improve physiological and neurological outcomes. It is authored by a team with prior experience developing medical technologies such as the BreatheRight® nasal strip, the FDA-cleared Q-Collar®, and the SAGE Rebreather™ mask.
April 2024 NEW PATENT APPROVED | USPTO issues a new SAGE patent providing added legal protection for its exciting and powerful SAGE Rebreather™ platform technology designed to avoid brain damage (TBI) from traumatic head impacts, among a variety of conditions, such as occur in sport or in war (or in training for either). Inventor DrDave™ Smith MD discovered two ways Mother Nature employs. Both models convert Brain SLOSH™ from inelastic to elastic collisions, which reduces energy absorption, passes it through, and minimizes its damaging effects.
neil@deltachase.com